Alnylam Pharmaceuticals
Alnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
Corporate information
- Company entity
- Alnylam Pharmaceuticals
- Headquarters / principal office
- Cambridge, Massachusetts, United States ↗
- Founded
- 2002 ↗
- Ownership / capital status
- Publicly tradedNasdaq ALNY ↗
- Official corporate reference
- https://www.alnylam.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Alnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.